73 related articles for article (PubMed ID: 38542325)
1. Genetic and Epigenetic Characterization of Sarcoma Stem Cells Across Subtypes Identifies EZH2 as a Therapeutic Target.
O'Donnell E; Muñoz M; Davis R; Randall RL; Tepper C; Carr-Ascher J
bioRxiv; 2024 May; ():. PubMed ID: 38798385
[TBL] [Abstract][Full Text] [Related]
2. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance.
Januchowski R; Wojtowicz K; Zabel M
Biomed Pharmacother; 2013 Sep; 67(7):669-80. PubMed ID: 23721823
[TBL] [Abstract][Full Text] [Related]
3. Aldehyde dehydrogenase-positive melanoma stem cells in tumorigenesis, drug resistance and anti-neoplastic immunotherapy.
Zhang S; Yang Z; Qi F
Mol Biol Rep; 2020 Feb; 47(2):1435-1443. PubMed ID: 31838656
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.
Cruz SM; Iranpur KR; Judge SJ; Ames E; Sturgill IR; Farley LE; Darrow MA; Crowley JS; Monjazeb AM; Murphy WJ; Canter RJ
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542325
[TBL] [Abstract][Full Text] [Related]
5. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway.
Takao T; Masuda H; Kajitani T; Miki F; Miyazaki K; Yoshimasa Y; Katakura S; Tomisato S; Uchida S; Uchida H; Tanaka M; Maruyama T
Stem Cell Res Ther; 2022 Jun; 13(1):225. PubMed ID: 35659728
[TBL] [Abstract][Full Text] [Related]
7. Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas.
Henderson T; Chen M; Darrow MA; Li CS; Chiu CL; Monjazeb AM; Murphy WJ; Canter RJ
J Surg Res; 2018 Mar; 223():207-214. PubMed ID: 29433875
[TBL] [Abstract][Full Text] [Related]
8. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A
Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001
[TBL] [Abstract][Full Text] [Related]
9. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.
Croker AK; Goodale D; Chu J; Postenka C; Hedley BD; Hess DA; Allan AL
J Cell Mol Med; 2009 Aug; 13(8B):2236-2252. PubMed ID: 18681906
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral NKp46
Cruz SM; Sholevar CJ; Judge SJ; Darrow MA; Iranpur KR; Farley LE; Lammers M; Razmara AM; Dunai C; Gingrich AA; Persky J; Mori H; Thorpe SW; Monjazeb AM; Murphy WJ; Canter RJ
Front Immunol; 2023; 14():1230534. PubMed ID: 37545516
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.
Lee TK; Guan XY; Ma S
Nat Rev Gastroenterol Hepatol; 2022 Jan; 19(1):26-44. PubMed ID: 34504325
[TBL] [Abstract][Full Text] [Related]
12. Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells.
Mohan A; Raj Rajan R; Mohan G; Kollenchery Puthenveettil P; Maliekal TT
Front Cell Dev Biol; 2021; 9():668851. PubMed ID: 34150761
[TBL] [Abstract][Full Text] [Related]
13. Enrichment of Melanoma Stem-Like Cells via Sphere Assays.
Mukherjee N; Lambert KA; Norris DA; Shellman YG
Methods Mol Biol; 2021; 2265():185-199. PubMed ID: 33704715
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of cancer stem cell formation and maintenance.
French R; Pauklin S
Int J Cancer; 2021 Jun; 148(12):2884-2897. PubMed ID: 33197277
[TBL] [Abstract][Full Text] [Related]
15. Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas.
Judge SJ; Darrow MA; Thorpe SW; Gingrich AA; O'Donnell EF; Bellini AR; Sturgill IR; Vick LV; Dunai C; Stoffel KM; Lyu Y; Chen S; Cho M; Rebhun RB; Monjazeb AM; Murphy WJ; Canter RJ
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158916
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
